| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
Chelidonic acid has been reported to exhibit various biological activities, but its specific molecular targets are not well-defined in the literature. As a γ-pyrone dicarboxylic acid, it may interact with enzymes or receptors through its carboxylate groups. Chelidonic acid derivatives have been studied for their effects on various biological pathways, but the primary molecular target of chelidonic acid itself remains to be fully characterized.
|
|---|---|
| ln Vitro |
Chelidonic acid has been reported to exhibit antimicrobial, anti-inflammatory, and anticancer activities in various studies. However, specific in vitro activity data for chelidonic acid monohydrate are limited. As a naturally occurring compound, it has been studied for its potential biological effects, but detailed pharmacological characterization is needed. The compound's activity may be related to its ability to chelate metal ions or interact with biological macromolecules.
|
| ln Vivo |
In vivo biological activity data for chelidonic acid monohydrate are limited. As a naturally occurring compound, it has been studied for its potential medicinal properties, but detailed in vivo efficacy studies have not been extensively reported. The compound is primarily used as a research chemical and reference standard. Further studies would be needed to evaluate its in vivo pharmacological profile.
|
| Enzyme Assay |
Chelidonic acid can be characterized by standard analytical methods including HPLC, NMR, and mass spectrometry. Its metal chelation properties can be assessed using spectroscopic methods. Enzyme inhibition assays can be performed to evaluate potential interactions with specific targets. However, specific assay protocols for chelidonic acid are not standardized in the literature.
|
| Cell Assay |
Cellular assays for chelidonic acid would typically involve treating various cell lines with the compound and assessing cell viability (MTT or CCK-8 assays), inflammation markers (cytokine ELISA), or antimicrobial activity. However, detailed published cellular assay protocols for chelidonic acid monohydrate are limited. The compound's potential cytotoxic effects would be evaluated using standard cytotoxicity screening methods.
|
| Animal Protocol |
In vivo studies with chelidonic acid have not been extensively reported. As a research chemical, it is not typically used in animal studies. If used, standard protocols for toxicity and efficacy evaluation in rodent models would apply. The compound would be administered via appropriate routes (oral, intraperitoneal, or intravenous), and parameters such as body weight, clinical signs, and tissue histology would be monitored.
|
| ADME/Pharmacokinetics |
Chelidonic acid monohydrate has molecular formula C7H6O7 (or C7H4O6·H2O) and molecular weight 202.12. The compound is a white to orange to green powder to crystal. It has CAS number 6003-94-7. The compound should be stored at room temperature in a cool, dry place. It is soluble in hot water.
|
| Toxicity/Toxicokinetics |
Toxicological data for chelidonic acid monohydrate are limited. As a naturally occurring compound, it is generally considered to have low toxicity, but specific toxicological data are not extensively reported. The compound should be handled with appropriate laboratory safety precautions. Standard safety data for similar compounds suggest potential irritancy at high concentrations.
|
| Additional Infomation |
Chelidonic acid monohydrate is a naturally occurring heterocyclic organic acid with a γ-pyrone (pyran) skeleton. It is isolated from Chelidonium majus and occurs naturally in plants of the Asparagales order. The compound is the hydrated crystalline form of chelidonic acid (4-oxo-4H-pyran-2,6-dicarboxylic acid). It is used as a research chemical and reference standard.
|
| Molecular Formula |
C7H6O7
|
|---|---|
| Molecular Weight |
202.1183
|
| Exact Mass |
202.011
|
| CAS # |
6003-94-7
|
| PubChem CID |
51346158
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
471.3ºC at 760 mmHg
|
| Melting Point |
265ºC
|
| Flash Point |
204ºC
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C(=O)O[H])=C([H])C(C([H])=C1C(=O)O[H])=O.O([H])[H]
|
| InChi Key |
KJZJAKSEIQOKAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H4O6.H2O/c8-3-1-4(6(9)10)13-5(2-3)7(11)12;/h1-2H,(H,9,10)(H,11,12);1H2
|
| Chemical Name |
4-oxopyran-2,6-dicarboxylic acid;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9476 mL | 24.7378 mL | 49.4756 mL | |
| 5 mM | 0.9895 mL | 4.9476 mL | 9.8951 mL | |
| 10 mM | 0.4948 mL | 2.4738 mL | 4.9476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
